Roth Puts A 'Buy' On Biotie...Firm Excited About 'Best In Class Treatment' For Parkinson's

By: via Benzinga
In a new report, Roth Capital analyst Elemer Piros initiated coverage of Biotie Therapies Oyj (ADR) (NASDAQ: BITI) with a Buy rating and ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.